Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Eledon Pharmaceuticals (ELDN) Return on Capital Employed (2016 - 2026)

Eledon Pharmaceuticals filings provide 4 years of Return on Capital Employed readings, the most recent being 65.31% for Q3 2017.

  • On a quarterly basis, Return on Capital Employed rose 551.0% to 65.31% in Q3 2017 year-over-year; TTM through Sep 2017 was 65.31%, a 551.0% increase, with the full-year FY2016 number at 16.71%, up 3869.0% from a year prior.
  • Return on Capital Employed hit 65.31% in Q3 2017 for Eledon Pharmaceuticals, down from 57.94% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 22.75% in Q4 2014 to a low of 118.12% in Q4 2016.
  • Median Return on Capital Employed over the past 4 years was 66.62% (2015), compared with a mean of 62.85%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -5019bps in 2016 and later surged 2165bps in 2017.
  • Eledon Pharmaceuticals' Return on Capital Employed stood at 22.75% in 2014, then crashed by -199bps to 67.93% in 2015, then tumbled by -74bps to 118.12% in 2016, then surged by 45bps to 65.31% in 2017.
  • The last three reported values for Return on Capital Employed were 65.31% (Q3 2017), 57.94% (Q2 2017), and 69.35% (Q1 2017) per Business Quant data.